CRH Medical Corp (NYSEAMERICAN:CRHM) – Research analysts at Cormark issued their Q3 2018 earnings estimates for CRH Medical in a report released on Wednesday, August 8th. Cormark analyst T. Gonsalves anticipates that the company will post earnings of $0.02 per share for the quarter. Cormark also issued estimates for CRH Medical’s Q4 2018 earnings at $0.04 EPS and FY2018 earnings at $0.09 EPS.

A number of other equities research analysts have also weighed in on the stock. Zacks Investment Research lowered shares of CRH Medical from a “buy” rating to a “hold” rating in a report on Tuesday, July 3rd. TD Securities upgraded shares of CRH Medical from a “hold” rating to a “buy” rating in a report on Friday, July 27th.

CRH Medical stock opened at $3.55 on Monday. CRH Medical has a 12-month low of $1.46 and a 12-month high of $3.75.

CRH Medical (NYSEAMERICAN:CRHM) last released its earnings results on Wednesday, August 1st. The company reported $0.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.01 by $0.01. The firm had revenue of $27.33 million during the quarter, compared to the consensus estimate of $25.70 million.

Several institutional investors have recently modified their holdings of CRHM. UBS Group AG boosted its stake in CRH Medical by 720.0% in the 1st quarter. UBS Group AG now owns 205,000 shares of the company’s stock worth $523,000 after purchasing an additional 180,000 shares in the last quarter. CIBC World Markets Inc. acquired a new stake in CRH Medical in the 2nd quarter worth approximately $722,000. Renaissance Technologies LLC boosted its stake in CRH Medical by 46.0% in the 2nd quarter. Renaissance Technologies LLC now owns 383,600 shares of the company’s stock worth $1,189,000 after purchasing an additional 120,800 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in CRH Medical by 1,221.7% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 591,665 shares of the company’s stock worth $1,849,000 after purchasing an additional 546,900 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in CRH Medical by 21.9% in the 1st quarter. JPMorgan Chase & Co. now owns 899,700 shares of the company’s stock worth $2,294,000 after purchasing an additional 161,800 shares in the last quarter.

About CRH Medical

CRH Medical Corporation provides various products and services to gastroenterologists for the treatment of gastrointestinal diseases in the United States, Canada, and internationally. It offers CRH O'Regan system, a single use, disposable, and hemorrhoid banding technology for treating various grades of hemorrhoid.

See Also: New Google Finance Tool and Screening Stocks

Earnings History and Estimates for CRH Medical (NYSEAMERICAN:CRHM)

Receive News & Ratings for CRH Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH Medical and related companies with MarketBeat.com's FREE daily email newsletter.